Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Biotechnology

Healthcare
$8.23 -0.67%

-$0.09 today

Market cap
$239.70M
Beta
0.99
P/E (TTM)
-4.3
EPS (TTM)
-$2.90
52W Low $6.44High $17.15

Volume 0.81M

Average 0.17M

Income Statement

Follow revenue through to earnings.

Revenue

$65.32M

FY 2025 · Annual

-3.4% YoY

Operating Income

-$85.35M

FY 2025 · Annual

Net Income

-$81.89M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue97.07M86.16M79.2M67.64M65.32M
Cost of Revenue00004.59M
Gross Profit97.07M86.16M79.2M67.64M60.74M
Gross Margin100.0%100.0%100.0%100.0%93.0%
Research & Development174.11M164.52M163.52M131.48M106.74M
Selling, General & Admin32.54M45.48M52.89M57.85M43.93M
Operating Expenses206.65M210M216.41M189.33M146.09M
Depreciation & Amortization3.33M2.97M2.37M2.34M5.09M
EBITDA(104.25M)(119.22M)(123.48M)(104.51M)(70.78M)
EBITDA Margin-107.4%-138.4%-155.9%-154.5%-108.4%
Operating Income(109.57M)(123.84M)(137.21M)(121.69M)(85.35M)
Operating Margin-112.9%-143.7%-173.2%-179.9%-130.7%
Interest Income2.02M1.57M11.36M14.77M9.48M
Interest Expense005.15M10.94M7.68M
Other Income / Expenses1.99M1.66M6.21M3.9M1.8M
Income Before Tax(107.58M)(122.19M)(131M)(117.79M)(83.55M)
Pre-Tax Margin-110.8%-141.8%-165.4%-174.2%-127.9%
Income Tax Expense(28.58M)(433K)2.82M(1.74M)(1.66M)
Net Income(79M)(121.76M)(133.82M)(116.05M)(81.89M)
Net Margin-81.4%-141.3%-169.0%-171.6%-125.4%
EPS (Basic)(3.92)(5.91)(6.38)(5.48)(3.84)
EPS (Diluted)(3.92)(5.91)(6.38)(5.48)(3.84)
Weighted Avg Shares20.17M20.6M20.97M21.16M21.34M
Weighted Avg Shares (Diluted)20.17M20.6M20.97M21.16M21.34M

ENTA Earnings Waterfall · TTM

NASDAQ:ENTA · Revenue to Net Income

Key Ratios

EPS$-2.74
Gross Margin98.2%
Net Margin-90.9%
P/E Ratio-4.5
P/S Ratio14.9

Analysis

$69.2M of revenue converted into -$62.0M of net income for the selected period. Gross margin is 98.2% and net margin is -90.9%, showing how much revenue survives after costs and taxes. EPS is $-2.74, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportOct 29, 2026
8-KCurrent reportOct 28, 2026
SC 13GSC 13G filingOct 27, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
SC 13G/ASC 13G/A filingAug 14, 2026

How much revenue does ENTA generate?

Enanta Pharmaceuticals, Inc. (ENTA) reported $65.32M of revenue in fiscal 2025.

Is ENTA profitable?

Enanta Pharmaceuticals, Inc. (ENTA) reported -$81.89M of net income, with a net margin of -125.4%.